<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04849351</url>
  </required_header>
  <id_info>
    <org_study_id>2020-689-00CH3</org_study_id>
    <nct_id>NCT04849351</nct_id>
  </id_info>
  <brief_title>Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma</brief_title>
  <official_title>A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of&#xD;
      HMPL-689 in Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) and Follicular&#xD;
      Lymphoma (FL)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, single-arm, open-label clinical study to evaluate the oral therapy&#xD;
      with HMPL-689 in patients with relapsed / refractory MZL and FL. Relapse / refractory is&#xD;
      defined as such a situation when a patient has not achieved response (CR or PR) after the&#xD;
      latest line of systemic treatment, or has disease progress (PD) or relapse after achieving&#xD;
      response. Two (2) cohorts of patients will be enrolled in this study:&#xD;
&#xD;
      Cohort 1: approximately 81 patients with histologically confirmed MZL&#xD;
&#xD;
      Cohort 2: approximately 104 patients with histologically confirmed FL (pathological grade&#xD;
      1-3a)&#xD;
&#xD;
      All patients are to receive monotherapy of HMPL-689 30 mg once a day (QD) continuously in&#xD;
      28-day treatment cycles until PD / recurrence, patient death, intolerable toxicity,&#xD;
      initiation of other antitumor therapy, the patient unable to further benefit from the study&#xD;
      treatment as judged by the investigators, the patient or his/her legal representative's&#xD;
      request to withdraw from the clinical study treatment, the patient lost to follow-up or end&#xD;
      of the study, whichever comes first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Baseline up to the last patient has completed 12 months after treatment.</time_frame>
    <description>Defined as the proportion of patients with CR or PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate</measure>
    <time_frame>Baseline up to the last patient has completed 12 months after treatment.</time_frame>
    <description>Defined as the proportion of patients with CR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Baseline up to the last patient has completed 12 months after treatment.</time_frame>
    <description>Defined as the time from the first dose of HMPL-689 to occurrence of PD or death, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Baseline up to the last patient has completed 12 months after treatment.</time_frame>
    <description>Defined as the time from the first dose of HMPL-689 to the first objective response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Baseline up to the last patient has completed 12 months after treatment.</time_frame>
    <description>Defined as the time from the initial objective response to disease recurrence, progression or death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Relapsed/Refractory MZL and FL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMPL-689</intervention_name>
    <description>All patients are to receive monotherapy of HMPL-689 30 mg QD continuously in 28-day treatment cycles.</description>
    <arm_group_label>Relapsed/Refractory MZL and FL</arm_group_label>
    <other_name>Phosphatidylinositol 3-kinase-δ inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years;&#xD;
&#xD;
          2. Patients with relapsed/refractory marginal zone lymphoma or follicular lymphoma&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status score 0-2;&#xD;
&#xD;
          4. At least one measurable lesion by computerised tomography (CT) / magnetic resonance&#xD;
             imaging (MRI) (the longest diameter of nodal lesion &gt; 1.5 cm or extranodal lesion &gt; 1&#xD;
             cm);&#xD;
&#xD;
          5. Expected survival of more than 12 weeks;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Having lymphoma with central nervous system (CNS) or cerebral pia mater invasion&#xD;
&#xD;
          2. Known histologic transformation to aggressive lymphomas such as diffuse large B-cell&#xD;
             lymphoma (DLBCL);&#xD;
&#xD;
          3. Prior use of any phosphatidylinositol 3-kinase (PI3K) inhibitor or Bruton's tyrosine&#xD;
             kinase (BTK) inhibitor&#xD;
&#xD;
          4. Inadequate organ function of liver and kidney&#xD;
&#xD;
          5. Currently known active infection with human immunodeficiency virus (HIV), hepatitis B&#xD;
             virus (HBV) or hepatitis C virus (HCV)&#xD;
&#xD;
          6. Having received systemic antitumor therapy or radiotherapy within 4 weeks prior to the&#xD;
             first dose of the investigational product&#xD;
&#xD;
          7. Toxicity of previous antitumor therapy not recovered to CTCAE grade ≤ 1, except&#xD;
             alopecia, prior to the first dose of the investigational product&#xD;
&#xD;
          8. Complicated with uncontrolled systemic infection requiring intravenous antibiotic&#xD;
             treatment&#xD;
&#xD;
          9. Pregnant (positive serum pregnancy test) or lactating women&#xD;
&#xD;
         10. Any other disease, metabolic abnormality, physical examination abnormality or&#xD;
             clinically significant laboratory test abnormality, one disease or state providing a&#xD;
             reason to suspect that the subject is not suitable for HMPL-689 at the investigator's&#xD;
             discretion, or one condition that will affect interpretation of the study results or&#xD;
             bring the subject at high risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>junning Cao, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhiming Li, post-doc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xianlin Duan</last_name>
    <phone>021-20678852</phone>
    <email>xianlind@hmplglobal.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meiping Kong</last_name>
    <phone>86 21 2067 3233</phone>
    <email>meipingk@hmplglobal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230601</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>zhimin Zhai, Ph.D</last_name>
      <email>Zzzm889@163.com</email>
    </contact>
    <investigator>
      <last_name>zhimin Zhai, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-yang Hospital ，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>aijun Liu, Ph.D</last_name>
      <email>laj0628@163.com</email>
    </contact>
    <investigator>
      <last_name>aijun Liu, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>zhao Wang, Ph.D</last_name>
      <email>zhaowww263@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>zhao Wang, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yuqing Song, post-doc</last_name>
      <email>SongYQ_VIP@163.com</email>
    </contact>
    <investigator>
      <last_name>yuqing Song, post-doc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>hongmei Jin, Ph.D</last_name>
      <email>Jinghm@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>hongmei Jin, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yao Liu, Ph.D</last_name>
      <email>648283926@qq.com</email>
    </contact>
    <investigator>
      <last_name>yao Liu, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yu Yang, Bachelor</last_name>
      <email>yangyu90l@l63.com</email>
    </contact>
    <investigator>
      <last_name>yu Yang, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>bing Xu, Ph.D</last_name>
      <email>xubingzhangjian@126.com</email>
    </contact>
    <investigator>
      <last_name>bing Xu, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhiming Li, Post-doc</last_name>
      <email>lzmsysu@163.com</email>
    </contact>
    <investigator>
      <last_name>zhiming Li, Post-doc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ru Feng, Master</last_name>
      <email>ruth1626@126.com</email>
    </contact>
    <investigator>
      <last_name>ru Feng, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <zip>515031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yingcheng Lin, Master</last_name>
    </contact>
    <investigator>
      <last_name>yingcheng Lin, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>hong Cen, Ph.D</last_name>
      <email>cen_hong@163.com</email>
    </contact>
    <investigator>
      <last_name>hong Cen, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>lier Lin, Master</last_name>
      <email>Linlier268@163.com</email>
    </contact>
    <investigator>
      <last_name>lier Lin, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puyang Oilfield General Hospital</name>
      <address>
        <city>Puyang</city>
        <state>Henan</state>
        <zip>410900</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>xuejun Guo, Master</last_name>
    </contact>
    <investigator>
      <last_name>xuejun Guo, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>keshu Zhou, Ph.D</last_name>
      <email>drzhouks77@163.com</email>
    </contact>
    <investigator>
      <last_name>keshu Zhou, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>zunmin Zhu, Ph.D</last_name>
      <email>huzm1964@163.com</email>
    </contact>
    <investigator>
      <last_name>zunmin Zhu, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ling Li, Ph.D</last_name>
      <email>LingL510@126.com</email>
    </contact>
    <investigator>
      <last_name>Ling li, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>liling Zhang, Ph.D</last_name>
      <email>lily1228@sina.com</email>
    </contact>
    <investigator>
      <last_name>liling Zhang, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>weiping Tao, Master</last_name>
      <email>taowpwp@sina.com</email>
    </contact>
    <investigator>
      <last_name>weiping Tao, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HuNan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>hui Zhou, Ph.D</last_name>
      <email>zhouhui9403@126.com</email>
    </contact>
    <investigator>
      <last_name>hui Zhou, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of YongZhou</name>
      <address>
        <city>Yongzhou</city>
        <state>Hunan</state>
        <zip>425006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>sijuan Ding, Master</last_name>
      <email>874663807@qq.com</email>
    </contact>
    <investigator>
      <last_name>sijuan Ding, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Nantong</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>meihua Ji, Master</last_name>
      <email>13813602152@163.com</email>
    </contact>
    <investigator>
      <last_name>meihua Ji, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>fei Li, Master</last_name>
      <email>yx021021@sina.com</email>
    </contact>
    <investigator>
      <last_name>fei Li, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>sujun Gao, Ph.D</last_name>
      <email>sujung1963@163.com</email>
    </contact>
    <investigator>
      <last_name>sujun Gao, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The affiliated hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>hongwei Xue, Ph.D</last_name>
      <email>hwx326@sina.com</email>
    </contact>
    <investigator>
      <last_name>hongwei xue, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>wenhao Zhang, Ph.D</last_name>
      <email>ZWHL98@FOXMAIL.COM</email>
    </contact>
    <investigator>
      <last_name>wenhao Zhang, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>junning Cao, Ph.D</last_name>
      <email>caojunning@126.com</email>
    </contact>
    <investigator>
      <last_name>junning Cao, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Bethune Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>30002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>qiaohua Zhang, Bachelor</last_name>
      <email>4792158@qq.com</email>
    </contact>
    <investigator>
      <last_name>qiaohua zhang, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>liqun Zou, Ph.D</last_name>
      <email>zliqun@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>liqun Zou, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of North Sichuan Medical College</name>
      <address>
        <city>Nanchong</city>
        <state>Sichuan</state>
        <zip>637000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>jin Wei, Master</last_name>
      <email>1497058875@qq.com</email>
    </contact>
    <investigator>
      <last_name>jin Wei, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>shiyong Zhou, Ph.D</last_name>
      <email>zsy1003@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>shiyong Zhou, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated to Xinjiang Medical University</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <zip>830000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>shune Yang, Master</last_name>
      <email>yangshune@yeah.net</email>
    </contact>
    <investigator>
      <last_name>shune Yang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>jin Liang, Master</last_name>
      <email>liangjinkm@163.com</email>
    </contact>
    <investigator>
      <last_name>jin Liang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>zhen Cai, Ph.D</last_name>
      <email>caizhen1@sina.com</email>
    </contact>
    <investigator>
      <last_name>zhen Cai, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>haiyan Yang, Ph.D</last_name>
      <email>haiyanyang1125@163.com</email>
    </contact>
    <investigator>
      <last_name>haiyan Yang, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yi Chen, Bachelor</last_name>
      <email>Chenyi9527@163.com</email>
    </contact>
    <investigator>
      <last_name>yi Chen, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Marginal Zone Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Phosphatidylinositol 3-kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

